Top Story

Expansion of ‘Right to Try’ legislation raises ethical, safety concerns

HemOnc Today, April 25, 2015

Early access to experimental drugs has historically been reserved for patients enrolled on clinical trials.

In 2009, the FDA revamped its 1980’s expanded access program, which allows terminally ill patients ineligible for clinical trials and for whom no alternative, approved therapies exist to ask pharmaceutical companies for access to an investigational drug in their pipeline. More than 1,500 patients received an experimental treatment through the FDA’s program in 2014.

Hemant Murthy, MD In PracticePublication Exclusive

State of the science: High-priority transplant trials for nonmalignant disease

HemOnc Today, April 25, 2015
Hemant Murthy, MD; William Wood, MD
Last June, we launched a series of columns in HemOnc Today intended to discuss high-priority proposals that emerged from the 2014 Blood and Marrow Transplant Clinical…
FDA News

FDA approves Cyramza for mCRC

April 24, 2015
The FDA today announced the approval of ramucirumab for use in combination with FOLFIRI chemotherapy for the treatment of certain patients with metastatic colorectal…
NAFLD-related HCC increasing in US, expected to continue Meeting News Coverage

NAFLD-related HCC increasing in US, expected to continue

April 24, 2015
VIENNA — As non-alcoholic fatty liver disease reaches ‘epidemic’ status, its relation to hepatocellular carcinoma is also on the rise with a higher…
In the Journals

Transoral robotic surgery alone acceptable for oropharyngeal cancer

April 24, 2015
Transoral robotic surgery, or TORS, alone resulted in acceptable short- and long-term quality-of-life outcomes in well-chosen patients with oropharyngeal squamous cell…
More News Headlines »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
VIDEO: Immunotherapy developments show 'real promise' in melanoma

VIDEO: Immunotherapy developments show 'real promise' in melanoma

April 16, 2015
Steven J. O’Day, MD, discusses new advancements in immunotherapies and checkpoint inhibitors — such as…
More »
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
morganatic-roan